Why One Drug Company Held Back a Better Drug

Last night, President Trump welcomed Xi Jinping, China’s top leader, in a lavish ceremony as he arrived for two days of closely watched negotiations.Artificial intelligence — and what, if any, role the countries should play in regulating it as concerns mount about its risks — is ...  Show more

More and more people are wearing technology in the form of fitness bands and smart rings. These devices track metrics such as heart rate, skin temperature and sleep. The latest frontier is health tech for babies — and it’s being supercharged by artificial intelligence.Sapna Mahes ...  Show more

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more

Gilead Sciences announced today that it will charge the U.S. government and other developed countries $390 per vial for its coronavirus-fighting drug remdesivir. That begins to answer a big question as drug companies race to find treatments and develop vaccines for the virus: How ...  Show more

Between 2006 and 2016, the number of drug patents granted in the United States doubled -- but not because there was an explosion in invention or innovation. Drug companies have learned how to game the system, accumulating patents not for new medicines but for small changes to exi ...  Show more

John Green recently made a video asking Johnson & Johnson not to extend their patent on a tuberculosis drug, which would keep it exclusive and expensive. Dr. Sydnee and Justin talk about how drug patents work, the recent (good) update about bedaquiline specifically, and the ne ...